This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
The efficacy and safety of remdesivir and its combination with other drug for the treatment of COVID-19: a systematic review and meta-analysis (preprint)
researchsquare; 2022.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2150443.v1
ABSTRACT
Background Remdesivir was considered to be a specific drug for Corona Virus Disease 2019. This systematic review aims to evaluate remdesivir monotherapy and combination therapy related clinical efficacy and risk. Research design and methods PubMed, Embase, SCIE, Cochrane Library, and American Clinical trial Center were searched up to 1 April 2022. We included randomized controlled trials (RCTs) comparing Remdesivir monotherapy with control drugs, or comparing different combination therapy. Results 11 RCTs and 32 observational studies were included in analysis. In the main outcome, remdesivir use reduced mortality in patients with severe COVID-19 and improve recovery in patients. In other clinical outcomes, remdesivir use was associated with improved clinical status. In safety outcomes, remdesivir use did not cause liver or kidney damage. Compared with remdesivir alone, remdesivir combined with other drugs-steroids, favipiravir, and convalescent plasma- had no effect on mortality. In addition, remdesivir combined with tocilizumab may increase mortality. Conclusion Results of the systematic review showed that remdesivir was positive in COVID-19, especially patients with severe COVID-19. The more effective treatment of COVID-19 with other drugs combined with remdesivir is urgent and challenging research. Trial registration number PROSPERO registration number CRD42022322859.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
COVID-19
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS